16 September 2026 editorial review · Trial
Sotagliflozin plus volagidemab adjunct combination: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected estimated24 enrollment falsely described asactualcompleted enrollment; specified keyeligibility. Corrected direct item relationships; shared class or background is insufficient.
Registry: NCT05696366. Endpoint reviewed: Change in HbA1c (12 weeks). Eligibility reviewed: Age 18 Years to 70 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.